1-fluoro-2-iodo-5-methyl-4-nitrobenzene | 259860-34-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-fluoro-2-iodo-5-methyl-4-nitrobenzene
• CAS: 259860-34-9
• 化学式: C₇H₅FINO₂
• 分子量: 281.025
• InChiKey: DPEVXZFONRKZFU-UHFFFAOYSA-N

物化性质

• 熔点：
  46.5-47.5 °C
• 沸点：
  293.8±35.0 °C(Predicted)
• 密度：
  1.953±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-fluoro-2-iodo-5-methyl-4-nitrobenzene 在 potassium fluoride 、 氢氧化钾 、 copper(l) iodide 、 铁粉 、 溶剂黄146 作用下， 以 乙醇 、 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 生成 (S)-1-[2-(tert-butoxycarbonylamino)propyl]-5-fluoro-6-trifluoromethylindole
  参考文献：
  名称：

  Indoline derivatives as 5-HT 2C receptor agonists

  摘要：

  A series of 1-(1-indolinyl)-2-propylamines was synthesised and evaluated as 5-HT2C receptor agonists for the treatment of obesity. The general methods of synthesis of the precursor indoles are described. The functional efficacy and radioligand binding data for all of the compounds at 5-HT2 receptor subtypes are reported. A number of compounds were found to reduce food intake in rats after oral administration. (C) 2004 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2003.05.001
• 作为产物：
  描述：

  2-氟-4-甲基-5-硝基苯胺 在 盐酸 、 sodium nitrite 、 potassium iodide 作用下， 以 水 为溶剂， 反应 3.0h， 以80%的产率得到1-fluoro-2-iodo-5-methyl-4-nitrobenzene
  参考文献：
  名称：

  [EN] CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREFOR
  [FR] DIARYLTHIAZÉPINEAMINES CARBOXYLIQUES ET LEURS UTILISATIONS

  摘要：

  本公开提供一种具有以下结构的化合物：公式（I）或其药学上可接受的盐或酯，用于治疗或预防神经系统疾病，包括亨廷顿病、雷特综合征和CDKL5疾病。

  公开号：

  WO2022074589A1

文献信息

• [EN] SUBSTITUTED 3, 4 - DIHYDRO - 2H - PYRIDO [1, 2 -A] PYRAZINE - 1, 6 - DIONE DERIVATIVES USEFUL FOR THE TREATMENT OF (INTER ALIA) ALZHEIMER'S DISEASE<br/>[FR] DÉRIVÉS DE 3,4-DIHYDRO-2H-PYRIDO[1,2-A]PYRAZINE-1,6-DIONE SUBSTITUÉS POUVANT ÊTRE UTILISÉS POUR LE TRAITEMENT DE (ENTRE AUTRES) LA MALADIE D'ALZHEIMER
  申请人：JANSSEN PHARMACEUTICALS INC

  公开号：WO2013171712A1

  公开（公告）日：2013-11-21

  The present invention is concerned with novel substituted 3,4-dihydro-2H-pyrido[1,2- a]pyrazine-1,6-dione derivatives of Formula (I) wherein R1, R2, R3, R4, R5, Z and X have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

  本发明涉及新颖的Formula (I)中的取代3,4-二氢-2H-吡啶并[1,2-a]吡嗪-1,6-二酮衍生物，其中R1、R2、R3、R4、R5、Z和X的含义如权利要求中所定义。根据本发明的化合物可用作γ-分泌酶调节剂。本发明还涉及制备这种新颖化合物的方法，包括将这些化合物作为活性成分的药物组合物，以及将这些化合物用作药物的用途。
• [EN] SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES BICYCLIQUES SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE PRMT5
  申请人：LUPIN LTD

  公开号：WO2019116302A1

  公开（公告）日：2019-06-20

  The invention relates to substituted bicyclic heterocyclic compounds of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.

  这项发明涉及公式（I）的取代双环杂环化合物，其药学上可接受的盐以及用于治疗与PRMT5 5酶过度表达相关的疾病、紊乱或状况的药物组合物。该发明还涉及治疗与PRMT5酶过度表达相关的疾病、紊乱或状况的方法。
• [EN] CARBOXYLIC DIARYTHIAZEPINEAMINES AS MIXED MU-AND DELTA-OPIOID RECEPTOR AGONISTS<br/>[FR] DIARYTHIAZÉPINAMINES CARBOXYLIQUES EN TANT QU'AGONISTES MIXTES DE RÉCEPTEUR D'OPIOÏDE MU ET DELTA
  申请人：UNIV COLUMBIA

  公开号：WO2018170275A1

  公开（公告）日：2018-09-20

  The present invention provides a compound having the structure:, or a pharmaceutically acceptable salt or ester thereof, and a method of treating a subject afflicted with a pain, a depressive disorder, a mood disorder, an anxiety disorder, borderline personality disorder, opioid addiction, or opioid withdrawal symptoms by administering the compound to the subject.

  本发明提供一种具有以下结构的化合物，或其药用可接受的盐或酯，以及通过向受到疼痛、抑郁障碍、情绪障碍、焦虑障碍、边缘人格障碍、阿片类成瘾或阿片类戒断症状困扰的对象施用该化合物的方法。
• [EN] INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS<br/>[FR] DERIVES D'INDOLINE UTILISES COMME LIGANDS DES RECEPTEURS 5-HT2B ET/OU 5-HT2C
  申请人：CEREBRUS PHARM LTD

  公开号：WO2000012475A1

  公开（公告）日：2000-03-09

  For use in therapy a chemical compound of formula (I), wherein R1 to R3 are independently selected from hydrogen and alkyl; R4 to R7 are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, heterocyclyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxyl, alkylsulfonyl, arylsulfoxyl, arylsulfonyl, amino, monoalkylamino, dialkylamino, nitro, cyano, carboxaldehyde, alkylcarbonyl, arylcarbonyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonylamino, aminocarbonyloxy, monoalkylaminocarbonyloxy, dialkylaminocarbonyloxy, monoalkylaminocarbonylamino and dialkylaminocarbonylamino, wherein at least one of R4 to R7 is a substituent group other than hydrogen, and pharmaceutically acceptable salts and prodrugs thereof, particularly for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and especially for the treatment of obesity; chemical compounds of formula (I) other than compounds wherein R7 is hydroxy.

  用于治疗的化合物的化学式（I），其中R1至R3分别选择氢和烷基；R4至R7分别选择氢，卤素，羟基，烷基，芳基，杂环基，烷氧基，芳氧基，烷硫基，芳硫基，烷基亚砜基，烷基磺酰基，芳基亚砜基，芳基磺酰基，氨基，单烷基氨基，双烷基氨基，硝基，氰基，羰基，烷基羰基，芳基羰基，氨基羰基，单烷基氨基羰基，双烷基氨基羰基，烷氧羰基氨基，氨基羟基羰基氧基，单烷基氨基羟基羰基氧基，双烷基氨基羟基羰基氧基，单烷基氨基羰基氧基和双烷基氨基羰基氧基，其中R4至R7中至少有一个是除氢外的取代基团，以及其药学上可接受的盐和前药，特别用于治疗中枢神经系统紊乱，中枢神经系统损伤，心血管疾病，胃肠道疾病，尿崩症和睡眠呼吸暂停，尤其用于治疗肥胖症；化学式（I）的化合物，除了其中R7为羟基的化合物。
• Benzofuran-3-yl(indol-3-yl) Maleimides as Potent GSK3 Inhibitors
  申请人：KOZIKOWSKI Alan P.

  公开号：US20100004308A1

  公开（公告）日：2010-01-07

  Compounds of formula: and pharmaceutically acceptable salts, esters and solvates thereof, where variables are defined in the specification, useful generally as inhibitors of protein kinases and particularly useful for inhibition of GSK-3. Pharmaceutically compositions and medicaments containing a compound of the invention are provided. The invention provides methods of treatment of protein kinase-related disease, disorders or conditions. The invention provides methods of treatment of GSK-3-related diseases, disorders or conditions. More specifically, methods of treatment of bipolar disorder, including mania, schizophrenia, stroke, epilepsy, motor neuron disease, cranial or spinal trauma, neurodegenerative disorders, including multiple sclerosis (MS), Alzheimer's disease, Fragile X syndrome, autism, Huntington's disease, Parkinson's disease, amylotrophic lateral sclerosis (ALS), AIDS-associated dementia, diabetes, particularly type II diabetes, cardiomycete hypertrophy, reperfusion/ischemia, cancer, particularly colorectal cancer, pancreatic cancer, allergies and/or asthma and hair loss or baldness.

  该化合物的公式：以及其药学上可接受的盐、酯和溶剂化物，其中变量在说明书中定义，通常用作蛋白激酶抑制剂，特别是用于抑制GSK-3。提供了含有发明化合物的药学组合物和药物。本发明提供了治疗蛋白激酶相关疾病、紊乱或病况的方法。本发明提供了治疗GSK-3相关疾病、紊乱或病况的方法。更具体地，本发明提供了治疗双相情感障碍、包括躁狂、精神分裂症、中风、癫痫、运动神经元疾病、头部或脊柱创伤、神经退行性疾病、包括多发性硬化症（MS）、阿尔茨海默病、脆性X综合征、自闭症、亨廷顿病、帕金森病、肌萎缩性脊髓侧索硬化症（ALS）、艾滋病相关痴呆、糖尿病，特别是II型糖尿病、心肌肥厚、复灌/缺血、癌症，特别是结肠癌、胰腺癌、过敏和/或哮喘以及脱发或秃发的方法。